Analysts await Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) to report earnings on May, 09 for the fiscal quarter ending Mar 2016.

They expect $0.13 EPS, down 1046.15% or $1.36 from last year’s $1.49 per share.

At the moment 4 analysts are watching Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), 0 rate it “Buy”, 1 “Outperform”, 2 “Underperform”, 1 “Sell”, while 0 “Hold”.

Looking forward, for the quarter ending Mar-16, 3 analysts have a mean sales target of 16.80 million. For the quarter ending Jun-16, 3 analysts have a mean sales target of 16.63 million whilst for the year ending Sep-16, 4 analysts have a mean target of 95.94 million.

In terms of earnings per share, 4 analysts have a 0.14 EPS mean target for the quarter ending Mar-16, for the quarter ending Jun-16, 4 analysts have a 0.04 EPS mean target and for the quarter ending Jun-16 there are 4 estimates of 1.45 EPS.

The biggest institutional shareholders in Enanta Pharmaceuticals, Inc. include Shionogi & Co Ltd which owns 2 million shares in the company valued at $52.82 million. Apex Capital Management is the second biggest holder with 1 million shares currently valued at 39.97 million whilst BlackRock Fund Advisors has 1 million shares valued at 37.98 million.

Total shares held by institutions as of the most recent company filings are 17,463,696 with a reported 992,517 bought and 1,230,818 sold. These holdings make up 92.3% of the company’s outstanding shares.

Currently insiders hold 999,764 shares in the business which makes up 5.28% of shares. The biggest holder currently is Dr. Jay R. Luly who owns 563,654 shares (2.98% of those outstanding), whilst Dr. Yat Sun Or holds 329,718 (1.74% of shares outstanding) and Mr. Paul J. Mellett holds 67,086 (0.35% of shares outstanding).

The stock decreased 0.24% or $0.06 during the last trading session, hitting $33.74. Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has risen 3.08% over the past 6 months and is uptrending.